secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atea Pharmaceuticals, Inc. (AVIR)
CIK:        0001593899
Form:       8-K
Filed at:   2021-08-12T23:59:59+00:00
Accession:  0001193125-21-244683
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atea reports Q2 net income $1.5M; AT-527 lung data positive, Phase 3 data due 2H21
--------------------------------------------------------------------------------

- Net income $1.5M vs net loss $10.0M YoY; collaboration revenue $60.4M from Roche.
- Cash $816.5M at June 30; $50M Roche milestone payment received in July 2021.
- AT-527 active metabolite achieved target antiviral levels in lung lining fluid in healthy volunteers.
- Phase 2 interim showed 0.7 log10 greater viral load reduction vs placebo at Day 2.
- Phase 3 MORNINGSKY and Phase 2 MOONSONG top-line results expected in 2H 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1593899/000119312521244683/0001193125-21-244683-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1593899/000119312521244683/d360425d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-244683

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer